^
    CANCER:

    Cutaneous Melanoma





    Show legend
    Group by Gene:
    Include preclinical:

    pembrolizumab
    		0
    PD1 inhibitor
    nivolumab
    PD1 inhibitor
    1
    PD1 inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab
    pembrolizumab + ipilimumab
    dacarbazine
    		2
    DNA synthesis inhibitor
    temozolomide
    cisplatin + dacarbazine
    3
    PD1 inhibitor, LAG-3 inhibitor
    nivolumab / relatlimab
    4
    CTLA4 inhibitor
    ipilimumab
    5
    PD1 inhibitor, BRAF inhibitor
    pembrolizumab + dabrafenib
    6
    Bcl2 inhibitor, Tubulin inhibitor
    albumin-bound paclitaxel
    7
    GM-CSF agonist, CTLA4 inhibitor
    ipilimumab + talimogene laherparepvec
    8
    GM-CSF agonist
    talimogene laherparepvec
    MEK inhibitor
    		9
    MEK inhibitor
    trametinib
    AS703026
    binimetinib
    10
    MEK inhibitor, BRAF inhibitor
    BRAF inhibitor + MEK inhibitor
    trametinib + dabrafenib
    11
    IFNα 2b stimulant
    interferon α-2b
    12
    TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
    larotrectinib
    13
    BRAF inhibitor
    BRAF inhibitor
    dabrafenib
    14
    BRAF inhibitor, BRAF V600E inhibitor
    vemurafenib
    15
    VEGF-A inhibitor
    bevacizumab
    16
    gp100 inhibitor
    tebentafusp-tebn
    17
    Immunotherapy
    Immunotherapy
    CVD
    		18
    Chemotherapy
    CaT
    TC
    19
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PD1 inhibitor, c-KIT inhibitor, PDGFR α antagonist
    pembrolizumab + lenvatinib
    20
    PD1 inhibitor, MEK inhibitor
    pembrolizumab + trametinib
    21
    Tubulin polymerization promoter, DNA synthesis inhibitor, Bcl2 inhibitor, Tubulin inhibitor
    paclitaxel + albumin-bound paclitaxel + dacarbazine
    22
    TLR7 agonist, TLR8 agonist
    imiquimod
    23
    Tubulin polymerization promoter, Bcl2 inhibitor
    paclitaxel
    24
    PD1 inhibitor, GM-CSF agonist
    PD1 inhibitor + talimogene laherparepvec
    25
    cRAF inhibitor, MEK inhibitor, BRAF inhibitor
    binimetinib + encorafenib
    26
    TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor inhibitor, ALK inhibitor, JAK2 inhibitor, TNK2 inhibitor
    entrectinib
    27
    BRAF inhibitor, MEK1 inhibitor, BRAF V600E inhibitor
    vemurafenib + cobimetinib
    28
    Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    dasatinib
    29
    MAP4K2 inhibitor, TAK1 inhibitor
    TL-1-85
    30
    PD-L1 inhibitor, gp100 inhibitor
    durvalumab + tebentafusp-tebn
    31
    PDGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor
    imatinib
    32
    PD-L1 inhibitor, BRAF inhibitor, MEK1 inhibitor, BRAF V600E inhibitor
    atezolizumab + vemurafenib + cobimetinib
    33
    HER2-targeted antibody-drug conjugate, Microtubule inhibitor
    ado-trastuzumab emtansine
    34
    JAK2 inhibitor, FLT3 inhibitor
    fedratinib
    35
    JAK1 inhibitor, JAK2 inhibitor
    ruxolitinib
    36
    PKC inhibitor
    IDE196
    37
    BET inhibitor
    JQ-1
    38
    VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor
    sunitinib
    No biomarker
    BRAF V600
    BRAF V600K
    BRAF wild-type
    BRAF V600E
    BRAF mutation
    TERT amplification
    NRAS mutation
    IFIT1 overexpression
    PAPPA2 mutation
    PAPPA2 mutation + TMB-H
    CTLA4 expression
    PD-1 expression
    HLA-A*02:01
    SLC35A2 overexpression
    NTRK2 fusion
    GOLGA4-RAF1 fusion
    HER-2 amplification
    NTRK1 fusion
    NTRK3 fusion
    KIT mutation
    PD-L1 expression
    CXCL10 elevation
    JAK2 underexpression
    PCSK9 underexpression
    ACSL4 overexpression
    FSIP2 mutation
    IFIT3 overexpression
    TASL expression
    PRKCH-SPTB fusion
    PRKCH fusion
    HIF1A-PRKCH fusion
    PRKCH-VWA2 fusion